Q2 FY2026 EarningsQ2 FY26 results beat revenue expectations but missed significantly on GAAP earnings, with a net loss of $8.97M compared to a projected $8.57M loss. Revenue of $7.90M exceeded the $6.35M consensus, primarily driven by the integration of BioTissue assets which contributed $6.71M in hospital sales. However, adjusted EPS of -$0.52 missed the $0.05 normalized expectation due to a 346% YoY surge in COGS and increased sales commissions following the acquisition. Management highlighted substantial doubt regarding the company's ability to continue as a going concern due to upcoming $10M FDA-related contingent payments and reduced Medicare reimbursement rates.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: BioStem Tech(BSEM) the Revenue is 7.899 M (-83.98%), Beat estimate;the EBIT is -8.401 M (-7550%), Beat estimate;the EPS is -0.52 (-1633%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B83.98%
0.01B87.11%
+0.00B3.13%
EBITExceed expectations
-0.01B7550.06%
-0.01B7701.10%
+0.00B151.04%
EPSMiss expectations
-0.521633.33%
-0.51566.67%
-0.020066.66%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf